April 25, 2024
Market Now
Kolon Life Science inks US$153m deal in China
[DISCLOSURE] Kolon Life Science (102940) announced on July 18 that it has signed a US$153 million contract with China Life Medical Centre to supply Invossa-K.
This amounts to 146.2 percent of its 2017 revenue and the contract is valid for 5 years from gaining approval from Hainan Province’s food and drug administrations.
By Hwang You-mee (glamazon@heraldcorp.com)
This amounts to 146.2 percent of its 2017 revenue and the contract is valid for 5 years from gaining approval from Hainan Province’s food and drug administrations.
By Hwang You-mee (glamazon@heraldcorp.com)
![[From the Scene] KG Mobility poised to take next leap](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=151&simg=/content/image/2024/04/24/20240424050621_0.jpg)
